



ITW

Docket No: LD0275A CIP

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Elliott Korsen
Type or print name

Signature

November 22, 2004
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1624

Salvati *et al.*

Examiner: **Kahsay Habte**

APPLICATION NO: 10/672,850

FILED: **September 26, 2003**

**FOR: PYRROLOPYRIDAZINE COMPOUNDS AND METHODS OF
USE THEREOF FOR THE TREATMENT OF
PROLIFERATIVE DISEASES**

MAIL STOP: Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO RESTRICTION REQUIREMENT

This paper is filed in response to the Office Action mailed October 22, 2004. The examiner has required restriction of the claims under 35 U.S.C. 121 as follows:

Group I Claims 1-6 (in part), 7-9, 10 (in part) and 15 (in part), drawn to pyrrolopyridazine compounds (bicyclic), simple composition and method of use (i.e. R₁, R₂ and X taken together don't form a ring);

Group II Claims 1-6 (in part), 10 (in part) and 15 (in part), drawn to pyrrolopyridazine compounds fused to a heterocyclic ring (tricyclic), simple composition and method of use (i.e. R₁, R₂ and X taken together form a heterocyclic ring);

Group III Claims 1-6 (in part), 10 (in part) and 15 (in part), drawn to pyrrolopyridazine compounds fused to form an aryl or a cycloalkyl ring (tricyclic), simple composition and method of use (i.e. R₁, R₂ and X are taken together form an aryl or a cycloalkenyl ring; X= a bond, CH₂ or CO); and

Group IV Claims 11-14 and 16-20, drawn to a complex composition of pyrrolopyridazine compounds and method of use.

The Office has laid out the reasons why the inventions are distinct and concluded that restriction for examination purposes is proper. While disagreeing with the Office's rationale, Applicant elects, without traverse, the Group I claims.


The Office has noted that "if applicants elect Group II or Group III, a tentative election of species is required. If applicants elect Group IV, a tentative election of species and one additional ingredient is required." Since Group I has been elected, Applicants have not elected a species and expect examination of the entire Group.

In view of the foregoing, Applicants submit that the application is in condition for allowance and courteously solicit a Notice of Allowance.

If any fee due is not accounted for herein, please charge such fee to Deposit Account No. 19-3880. If any extension of time is required and not petitioned for, such extension is hereby petitioned for, and it is requested that any fee due in connection therewith be charged to the aforementioned Deposit Account.

The foregoing response is believed to be fully responsive to the outstanding Office Action. If a direct personal communication would advance the prosecution of this application, please contact the undersigned attorney at the telephone number listed below.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Elliott K", written over a horizontal line.

Elliott Korsen
for Applicants
Reg. No. 32,705

Date: November 22, 2004
Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
(609) 252-4741